Nirav Shah
Expertise in
31
conditions

Dr. Nirav Shah

Hematology
Clinical Cancer Center-Froedtert Hospital
8800 W Doyne Ave, 
Milwaukee, WI 
Offers Telehealth
Expertise in
31
conditions
Clinical Cancer Center-Froedtert Hospital
8800 W Doyne Ave, 
Milwaukee, WI 

Overview

Nirav Shah is a Hematologist practicing medicine in Milwaukee, Wisconsin.

Dr. Shah is highly rated in 31 conditions, according to our data. His clinical expertise encompasses Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 271 peer reviewed articles and participating in 8 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in PA

Hospital Affiliations

Froedtert Memorial Lutheran Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Children's Community Health
  • EPO
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Common Ground Healthcare
  • OTHER COMMERCIAL
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Network Health
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Clinical Cancer Center-Froedtert Hospital
8800 W Doyne Ave, Milwaukee, WI 53226

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Phase I/II, Open Label, Multicenter Study of Rapcabtagene Autoleucel in Adult Patients With CLL/SLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Phase I/II, Open Label, Multicenter Study of Rapcabtagene Autoleucel in Adult Patients With CLL/SLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Enrollment Status: Active_not_recruiting
Publish Date: April 03, 2026
Intervention Type: Drug, Biological
Study Drugs: YTB323, Ibrutinib
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
Enrollment Status: Completed
Publish Date: January 27, 2026
Intervention Type: Drug
Study Drugs: LOXO-305, Rituximab
Study Phase: Phase 1/Phase 2
RESOLUTION: A Double-blind, Randomized, Placebo-controlled, Phase II/III Study of the Efficacy and Safety of LAU-7b in the Treatment of Adult Hospitalized Patients With COVID-19 Disease
RESOLUTION: A Double-blind, Randomized, Placebo-controlled, Phase II/III Study of the Efficacy and Safety of LAU-7b in the Treatment of Adult Hospitalized Patients With COVID-19 Disease
Enrollment Status: Terminated
Publish Date: November 13, 2025
Intervention Type: Drug
Study Drug: Fenretinide
Study Phase: Phase 2/Phase 3
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Enrollment Status: Active_not_recruiting
Publish Date: May 28, 2025
Intervention Type: Drug
Study Drugs: LOXO-305, Ibrutinib, Acalabrutinib, Zanubrutinib
Study Phase: Phase 3
A Phase 2, Open-Label Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK-cell Neoplasms
A Phase 2, Open-Label Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK-cell Neoplasms
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drug: Tislelizumab
Study Phase: Phase 2
Phase II, Single-Arm, Open-label, Multicenter Study Evaluating the Efficacy of Adjunctive Zanubrutinib and CAR T-Cell Therapy in Aggressive B-Cell Non-Hodgkin's Lymphoma
Phase II, Single-Arm, Open-label, Multicenter Study Evaluating the Efficacy of Adjunctive Zanubrutinib and CAR T-Cell Therapy in Aggressive B-Cell Non-Hodgkin's Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: October 16, 2024
Intervention Type: Other, Biological, Drug
Study Drugs: Chimeric Antigen Receptor T-Cell Therapy, Zanubrutinib
Study Phase: Phase 2
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Enrollment Status: Completed
Publish Date: June 11, 2024
Intervention Type: Drug
Study Drug: STRO-001
Study Phase: Phase 1
A Phase II Single Arm Study of Nivolumab as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Hodgkin Lymphoma at Risk of Relapse or Progression
A Phase II Single Arm Study of Nivolumab as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Hodgkin Lymphoma at Risk of Relapse or Progression
Enrollment Status: Completed
Publish Date: December 05, 2023
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 2
View 7 Less Clinical Trials

271 Total Publications

The Children's Urgent Reduction of Forearm Fractures in the Emergency Department (CURFFED) project : a national prospective trainee-led collaborative audit of practice.
The Children's Urgent Reduction of Forearm Fractures in the Emergency Department (CURFFED) project : a national prospective trainee-led collaborative audit of practice.
Journal: Bone & joint open
Published: April 10, 2026
Similar Doctors
Expertise in
31
conditions
Dr. Timothy Fenske
Hematology
Expertise in
31
conditions
Dr. Timothy Fenske
Hematology

Froedtert And The Medical College Of Wisconsin Froedtert Hospital

9200 W Wisconsin Ave, 
Milwaukee, WI 
 (0.2 miles away)
414-805-3666
Languages Spoken:
English
See accepted insurances

Timothy Fenske is a Hematologist practicing medicine in Milwaukee, Wisconsin. Dr. Fenske is highly rated in 31 conditions, according to our data. His clinical expertise encompasses Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
15
conditions
Dr. Anita D'souza
Hematology
Expertise in
15
conditions
Dr. Anita D'souza
Hematology

Clinical Cancer Center-Froedtert Hospital

8800 W Doyne Ave, 
Milwaukee, WI 
 (0.3 miles away)
414-805-0505
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Anita D'souza is a Hematologist practicing medicine in Milwaukee, Wisconsin. Dr. D'souza is highly rated in 15 conditions, according to our data. Her clinical expertise encompasses Multiple Myeloma, Primary Amyloidosis, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Tissue Biopsy.

Expertise in
18
conditions
Dr. Joshua Field
Hematology
Expertise in
18
conditions
Dr. Joshua Field
Hematology

Cancer Center-Moorland Reserve Health Center

4805 S Moorland Rd, 
New Berlin, WI 
 (7.5 miles away)
414-805-0505
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joshua Field is a Hematologist practicing medicine in New Berlin, Wisconsin. Dr. Field is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Hemoglobinopathy, Hemolytic Anemia, Congenital Hemolytic Anemia, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Nirav Shah

How do I make an appointment with Dr. Nirav Shah?

You can book an appointment with Dr. Nirav Shah by calling their office at 414-805-0505. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Nirav Shah a top-rated expert for Mantle Cell Lymphoma (MCL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Nirav Shah is classified as an Elite expert for Mantle Cell Lymphoma (MCL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Nirav Shah specialize in?

While Dr. Nirav Shah is a Hematology, they have specific expertise in Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, and B-Cell Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Nirav Shah participate in research or clinical trials?

Yes. Dr. Nirav Shah has published 271 articles and abstracts on conditions like Mantle Cell Lymphoma (MCL). You can view a list of Dr. Nirav Shah's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Nirav Shah accept my insurance?

Dr. Nirav Shah accepts most major insurance plans, including Anthem BCBS and Aspirus Arise Health. We recommend calling the office directly at 414-805-0505 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shah's expertise for a condition
ConditionClose
View All 12 Distinguished Conditions
View All 15 Advanced Conditions
View All 30 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile